Evidence map›Paper›PMID 33893078›Full record

ArticleCancer genomics & proteomics

Profiling of Serum Extracellular Vesicles Reveals

Yuka Muramatsu-Maekawa, Kyojiro Kawakami, Yasunori Fujita, Manabu Takai, Daiki Kato, Keita Nakane, Taku Kato, Tomohiro Tsuchiya, Takuya Koie, Yuri Miura and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yuka Muramatsu-MaekawaDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Kyojiro KawakamiResearch Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Yasunori FujitaResearch Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Manabu TakaiDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Daiki KatoDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Keita NakaneDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Taku KatoDepartment of Urology, Asahi University Hospital, Gifu, Japan.
Tomohiro TsuchiyaDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Takuya KoieDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yuri MiuraResearch Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Masafumi ItoResearch Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; mizutech@gifu-u.ac.jp mito@tmig.or.jp.
Kosuke MizutaniDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan; mizutech@gifu-u.ac.jp mito@tmig.or.jp.
Gifu University · JPTokyo Metropolitan Institute of Gerontology · JPAsahi University · JPGifu University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo identify novel diagnostic markers for renal cell carcinoma (RCC), we analyzed miRNAs in serum extracellular vesicles (EVs). MATERIALS AND

methodsEVs were purified from serum of healthy controls and patients with localized and advanced RCC using T-cell immunoglobulin domain and mucin domain-containing protein 4 conjugated to magnetic beads. miRNA profiling of EVs was conducted by microarray analysis. miRNA expression was examined by quantitative reverse transcription-polymerase chain reaction. Lastly, proteomic analysis of RCC cells transfected with a miRNA inhibitor was performed to identify its potential targets.

resultsMicroarray analysis revealed that nine miRNAs were increased by more than 1.5-fold in EVs from patients with RCC. Among them, miRNA-4525 was significantly elevated; miRNA-4525 expression was higher in RCC tissue than in the adjacent normal tissue. Proteomic analysis identified alpha fetoprotein and albumin as its potential targets.

conclusionThese findings suggest the potential of miRNA-4525 in serum EVs as a novel biomarker for advanced RCC.

Indexed as

AdultBiomarkers, TumorCarcinoma, Renal CellExtracellular VesiclesFemaleHumansKidney NeoplasmsMaleMicroRNAsMiddle AgedTransfectionBiomarkers, TumorMicroRNAsMIRN4525 microRNA, humanextracellular vesiclemicroarray analysismirna-4525proteomic analysisRenal cell carcinoma

Identifiers

PMID33893078
PMCPMC8126334
OpenAlexW3154160458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.